Evidence map›Paper›PMID 34681752›Full record

ArticleInternational journal of molecular sciences2021

Impact of Host Immune Status on Discordant Anti-SARS-CoV-2 Circulating B Cell Frequencies and Antibody Levels.

Frédéric Coutant, Jean-Jacques Pin, Florence Morfin-Sherpa, Tristan Ferry, Stéphane Paul, Bruno Pozzetto, Myriam Normand, Pierre Miossec

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Frédéric CoutantImmunogenomics and Inflammation Research Team, University of Lyon, Edouard Herriot Hospital, 69003 Lyon, France.ORCID 0000-0003-2485-5284
Jean-Jacques PinDendritics-Edouard Herriot Hospital, 69003 Lyon, France.
Florence Morfin-SherpaVirology Department, Infective Agents Institute, National Reference Center for Respiratory Viruses, North Hospital Network, 69004 Lyon, France.
Tristan FerryDepartment of Infectious and Tropical Diseases, Hospices Civils of Lyon-Croix-Rousse Hospital, 69004 Lyon, France.
Stéphane PaulDepartment of Immunology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.ORCID 0000-0002-8830-4273
Bruno PozzettoGIMAP Team, CIRI, INSERM U1111, CNRS, UMR530, University Claude Bernard Lyon 1, CIC 1408 Vaccinology, 42023 Saint-Etienne, France.
Myriam NormandSAINBIOSE, INSERM, U1059, University of Lyon, 42270 Saint-Etienne, France.
Pierre MiossecImmunogenomics and Inflammation Research Team, University of Lyon, Edouard Herriot Hospital, 69003 Lyon, France.
Université Claude Bernard Lyon 1 · FR

Funding

Claude Bernard University Lyon 1 Anti-CoV-2Hospices Civils de Lyon Anti-CoV-2
6 · The paper itself

Abstract

Individuals with pre-existing chronic systemic low-grade inflammation are prone to develop severe COVID-19 and stronger anti-SARS-CoV-2 antibody responses. Whether this phenomenon reflects a differential expansion of antiviral B cells or a failure to regulate antibody synthesis remains unknown. Here, we compared the antiviral B cell repertoire of convalescent healthcare personnel to that of hospitalized patients with pre-existing comorbidities. Out of 277,500 immortalized B cell clones, antiviral B cell frequencies were determined by indirect immunofluorescence screening on SARS-CoV-2 infected cells. Surprisingly, frequencies of SARS-CoV-2 specific clones from the two groups were not statistically different, despite higher antibody levels in hospitalized patients. Moreover, functional analyses revealed that several B cell clones from healthcare personnel with low antibody levels had neutralizing properties. This study reveals for the first time a key qualitative defect of antibody synthesis in severe patients and calls for caution regarding estimated protective immunity based only on circulating antiviral antibodies.

Indexed as

AdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralAntibody FormationB-LymphocytesComorbidityCOVID-19FemaleHealth PersonnelHumansMaleMiddle AgedSARS-CoV-2Severity of Illness IndexAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2anti-SARS-CoV-2B cell repertoireCOVID-19human monoclonal antibodySARS-CoV-2

Identifiers

PMID34681752
PMCPMC8540683
OpenAlexW3205878569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.